RxDoctor Payments Data

Cecily Lesko, MD

Ophthalmology · Clifton, NJNPI 1558337246

Payments from drug & device makers

$1,020in general payments, 2019–2025

Across 27 payments — averaging $37.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$190
  • Alcon$148
  • Bausch & Lomb Americas Inc.$147
  • Tarsus Pharmaceuticals, Inc.$145
  • Glaukos Corporation$111
  • Oyster Point Pharma, Inc.$110
  • plus $168 from 6 others

What the payments were for

  • Food & beverage$1,00098%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,020 in reported general payments places this provider in the 40th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$232,861
Medicare patients
657
Services billed
2,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$64,938
LumiganBimatoprost25$18,230
Prednisolone Acetate150$7,866
Travoprost33$5,674
Latanoprost256$4,165
Loteprednol Etabonate14$3,804
Timolol Maleate64$3,063
Ketorolac Tromethamine89$2,891
Tobramycin-DexamethasoneTobramycin/Dexamethasone71$2,567
Brimonidine Tartrate20$2,353
MoxifloxacinMoxifloxacin Hcl105$1,730
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,423
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat57$837
Ofloxacin24$495
Tobramycin11$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$34$83,16868 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$12$3,80414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →